Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torben Arngrim

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Psychopharmacology|July 27, 2002
Olanzapine-induced galactorrheaRasmus W Licht, Torben Arngrim, Hilmar Cristensen
Clinical Drug Investigation|July 13, 2014
Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trialMichael Huss, Ylva Ginsberg, Torben Arngrim, et al.
Advances in Therapy|December 28, 2013
Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trialMichael Huss, Ylva Ginsberg, Torbjorn Tvedten, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 27, 2011
Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidateMichael Rösler, Ylva Ginsberg, Torben Arngrim, et al.
Ugeskrift for Laeger|January 29, 2009
[Adult screening for attention deficit hyperactivity disorder]Carsten Obel, Søren Dalsgaard, Torben Arngrim, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Psychopharmacology|July 27, 2002
Olanzapine-induced galactorrheaRasmus W Licht, Torben Arngrim, Hilmar Cristensen
Clinical Drug Investigation|July 13, 2014
Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trialMichael Huss, Ylva Ginsberg, Torben Arngrim, et al.
Advances in Therapy|December 28, 2013
Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trialMichael Huss, Ylva Ginsberg, Torbjorn Tvedten, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 27, 2011
Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidateMichael Rösler, Ylva Ginsberg, Torben Arngrim, et al.
Ugeskrift for Laeger|January 29, 2009
[Adult screening for attention deficit hyperactivity disorder]Carsten Obel, Søren Dalsgaard, Torben Arngrim, et al.
Pageof 1